Open an account

Penumbra

PEN · NYSE

$324.34+$1.93 (+0.60%)TodayMarket closed ·
Prev close $322.41

About PEN

Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,700 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

Employees
4,700
Headquarters
Alameda, California
Listed
Sep 18, 2015
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
penumbrainc.com

PEN key statistics

Market cap
12.78B
Price-earnings ratio
79.22
Dividend yield
—
Average volume
350.60K
Volume
368.83K
Open price
$322.99
High today
$324.64
Low today
$322.43
52 Week high
$362.41
52 Week low
$221.26

Penumbra (PEN) at a glance

Penumbra (PEN) last traded at $324.34, with a market cap of 12.78B and a price-to-earnings ratio of 79.22.

Today the stock has traded between $322.43 and $324.64. The current price is 0.6% above the day's low and 0.1% below its high.

Volume so far is 368.83K shares, in line with the average of 350.60K shares a day.

Over the past year Penumbra has ranged from $221.26 to $362.41, and now sits 73% of the way up that range.

Penumbra met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $0.88 per share against an estimate of $1.20.

The average analyst price target is $375.09, 15.6% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

21%of 14 analyst ratings say Buy
  • Buy21.4%
  • Hold78.6%
  • Sell0.0%
Price target · 16 analystsAvg $375.09
Low
$326.23
Now
$324.34
High
$407.40

PEN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 11.0% on average.

  1. Q3 FY24: reported $0.85 per share against an estimate of $0.6942
  2. Q4 FY24: reported $0.97 per share against an estimate of $0.9067
  3. Q1 FY25: reported $0.83 per share against an estimate of $0.6701
  4. Q2 FY25: reported $0.86 per share against an estimate of $0.8299
  5. Q3 FY25: reported $0.97 per share against an estimate of $0.9307
  6. Q4 FY25: reported $1.18 per share against an estimate of $1.12
  7. Q1 FY26: reported $0.82 per share against an estimate of $1.09
  8. Q2 FY26: reported $0.88 per share against an estimate of $1.20

PEN news

  • Press releasePRNewswire

    Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

  • Press releasePRNewswire

    New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism

  • Press releasePRNewswire

    Penumbra, Inc. Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

  • Press releasePRNewswire

    First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

  • Press releasePRNewswire

    Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT

  • Press releasePRNewswire

    Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke

  • Press releasePRNewswire

    New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients

Similar companies

Companies in the same industry as Penumbra

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.